drugset / Trial / NCT04955262
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to investigate the utility of the new investigational imaging agent ⁸⁹Zr Df-IAB22M2C (CD8 PET/CT tracer) to monitor CD8 T-cell expansion and trafficking within tumors and associated tissues in patients with metastatic melanoma undergoing treatment with bempegaldesleukin and nivolumab as a single agent and in combination.
Timeline
- Start
- 2019-08
- Primary completion
- 2021-06
- Completion
- 2022-01
Outcome
Outcome not reported
Stopped (Business): “Did not initiate due to business reasons. IND is inactive.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempegaldesleukin | Protein / enzyme biologic | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | ⁸⁹Zr-Df-IAB22M2C | Diagnostic / imaging agent | — | — |